Test | Patients tested n | |
FVC % pred | 61 | 90±18 (47–125) |
FEV1 % pred | 61 | 80±21 (33–123) |
Post-bronchodilator improvement in FEV1 L | 36 | 0.06±0.13 (−0.35–0.3) |
FEV1/FVC % | 61 | 69±13 (30–94) |
FEF25–75% % pred | 57 | 51±26 (15–118) |
TLC % pred | 56 | 88±17 (44–132) |
RV % pred | 56 | 90±32 (35–188) |
TL,CO % pred | 57 | 37±16 (10–80) |
KCO % pred | 57 | 46±19 (8–84) |
Pa,O2 at rest (supine position) kPa | 61 | 8.4±1.9 (4.6–13.3) |
Pa,CO2 at rest (supine position) kPa | 61 | 4.9±0.7 (3.0–7.3) |
Alveolar–arterial Pa,O2 difference (room air) kPa | 61 | 5.5±2.1 (0.1–11.7) |
Pa,O2 at exercise–Pa,O2 at rest (supine position) kPa | 22 | −1.5±1.6 (−4.4–1.7) |
6-min walking distance m | 23 | 336±139 (50–548) |
Decrease in SP,O2 during 6-min walking test % | 23 | −8.9±5.7 (−20–0) |